As both 5-FU and cisplatin chemo-immunotherapies increased activated and proliferating CD8+ and CD4+Foxp3- T cells, we depleted CD8+ or CD4+ T cells throughout the treatment schedule in AB1-HA tumor-bearing mice to test whether these cells were required for effective chemo‐immunotherapy. The gene discussed is FOXP3; the disease is neoplasm.